zolpidem has been researched along with Parkinson Disease, Secondary in 1 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zolpidem use might unmask preclinical Parkinson's disease, especially in patients with depression." | 3.81 | Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study. ( Huang, HC; Kao, CH; Lin, KH; Lu, MK; Muo, CH; Sung, FC; Tsai, CH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, HC | 1 |
| Tsai, CH | 1 |
| Muo, CH | 1 |
| Lin, KH | 1 |
| Lu, MK | 1 |
| Sung, FC | 1 |
| Kao, CH | 1 |
1 other study available for zolpidem and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzodiazepines; Comorbidity; Depression; Female; Humans | 2015 |